U.K. Government to Buy 60 Million Doses of Novavax COVID-19 Vaccine

Novavax (NASDAQ: NVAX) capped its week with the announcement that it has reached a deal with the U.K. government to supply that country with its COVID-19 vaccine candidate. The two sides signed a heads-of-terms agreement to supply the U.K. with 60 million doses of the company's NVX-CoV2373.

The agreement also includes a phase 3 clinical trial to be conducted in the country in order to determine the efficacy of NVX-CoV2373 on the nation's citizenry. This will involve roughly 9,000 adults ages 18 to 85 and is expected to launch in the third quarter of this year. The government will provide infrastructure and other forms of support for the trial.

Image source: Getty Images.

Continue reading

Source Fool.com